First Tracks Biotherapeutics
TRAX----
Q1 FY2026 Earnings
Financial report interval: 2025.12.31 - 2026.03.31
Preview: First Tracks Biotherapeutics(TRAX) predict that the EBIT is -52.81 M (--%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.01B--
----
EBITMiss expectations
-0.05B--
-0.03B--
-0.03B--%
EPS
TBA--
-0.6032--
----
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf